The rising popularity of Wegovy and Zepbound for weight loss prompts a key question: which is superior?
In a recent trial, Lilly reported that participants using Zepbound achieved approximately 20% body weight reduction after 18 months, compared to nearly 14% weight loss in those using Novo Nordisk’s Wegovy.
Both Wegovy (semaglutide) and Zepbound (tirzepatide) influence incretin hormones. Wegovy targets GLP-1, curbing appetite and stimulating insulin production. Zepbound acts on both GLP-1 and GIP, another insulin-stimulating hormone. While previous individual manufacturer studies indicated Zepbound’s greater efficacy, this trial offers the first direct comparison.
Novo Nordisk highlighted Wegovy’s additional health benefits. A spokesperson stated that Wegovy, alongside diet and exercise, is proven to reduce major cardiovascular event risks in adults with heart disease and obesity or overweight. The FDA approved labeling Wegovy to reflect this in March. Novo Nordisk emphasized its commitment to semaglutide research, exploring its potential applications in diverse conditions, including Alzheimer’s, kidney, and liver diseases.
Lilly is also investigating tirzepatide’s broader health effects, with data suggesting reduced heart failure and heart disease mortality. These findings will be submitted to a peer-reviewed journal and presented at a medical conference next year.
These results align with previous FDA approval studies but provide a crucial direct comparison. This may stimulate the development of multi-hormone medications for enhanced weight loss and overall health benefits. Lilly is developing a three-hormone drug targeting GLP-1, GIP, and glucagon. Both companies are exploring oral formulations of their currently injectable medications.
“`
